Skip to content

Immunome IMNM Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.14B+20.5%
Nuvation Bio logo
Nuvation BioNUVB
$1.43B+3.5%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$18K+100%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5K+25.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$9K0.0%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Immunome (IMNM) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $11K in Q1 2026.
How has Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 22.2% year-over-year, from $9K to $11K.
What is the long-term trend for Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 5 years (2020 to 2025), Immunome's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 61.5% compound annual growth rate (CAGR), from $1K to $11K.
What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.